In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

The best 4K Blu-ray players deliver the ultimate picture quality for watching movies and TV series at home. Although streaming services are popular, Blu-rays deliver video at a higher bitrate ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Merck (MRK) announced that the European Commission (EC) has approved two new indications for Keytruda, Merck’s anti-PD-1 therapy, in gynecologic cancers. The first approval is for Keytruda ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

Among other steps, Regeneron is trying to move patients to a newer, high-dose version of Eylea. Eylea HD sales accounted for about $300 million of the franchise total in the second quarter.

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best medical stocks to ...

I’m a Mobile Analyst at PCMag, which means I cover wireless phones, plans, tablets, ereaders, and a whole lot more. I’ve always loved technology and have been forming opinions on consumer ...